Compare EVO & AWF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVO | AWF |
|---|---|---|
| Founded | 1993 | 1993 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.3M | 868.3M |
| IPO Year | 2007 | N/A |
| Metric | EVO | AWF |
|---|---|---|
| Price | $1.82 | $10.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 41.4K | ★ 254.4K |
| Earning Date | 04-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.57% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | $10.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.80 | $9.85 |
| 52 Week High | $4.27 | $11.43 |
| Indicator | EVO | AWF |
|---|---|---|
| Relative Strength Index (RSI) | 39.03 | 40.47 |
| Support Level | N/A | $9.98 |
| Resistance Level | $1.97 | $10.23 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 17.65 | 8.57 |
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.